按药物类别、剂型、给药途径、通路和最终用户分類的失眠治疗市场－2025年至2032年全球预测

预计到 2032 年，失眠治疗市场将成长至 48.7 亿美元，复合年增长率为 5.91%。

关键市场统计数据
基准年 2024	30.7亿美元
预计年份：2025年	32.5亿美元
预测年份 2032	48.7亿美元
复合年增长率 (%)	5.91%

本文简要概述了塑造现代失眠治疗格局的治疗创新、临床压力和商业性驱动因素。

由于科技进步、患者期望的改变以及监管力度的加大，失眠治疗市场正在迅速发展。本执行摘要探讨了对药物研发、临床实践、分销和支付方参与等各相关人员当前及近期决策至关重要的主题。它全面概述了治疗方法创新、消费模式的转变以及支持治疗交付的基础设施，为寻求将投资与新机会相结合的领导者提供了清晰的切入点。

重点，本导言将失眠置于更广泛的医疗保健背景下进行探讨，阐述了合併的精神疾病和心血管代谢疾病如何影响治疗方案的选择和患者的依从性。它重点强调了药物差异、安全性以及给药便利性如何日益影响临床医生的偏好和患者的接受度。本节概述了用于解读趋势的方法论严谨性和多角度观点（临床、监管和商业性），为后续分析奠定了基础。我们鼓励读者专注于策略意义，而非历史销售指标。后续章节将重点阐述可操作的见解，以支援产品组合和市场进入决策。

本文分析了正在重塑失眠药物研发和应用格局的、模式转移的临床进展、支付方期望以及医疗服务创新。

失眠治疗领域正经历一场变革浪潮，其驱动力包括作用机制的创新、安全性期望的提高以及数位化医疗路径的拓展。针对Orexin受体的新型化合物正在重塑临床上关于疗效和次日起效的讨论，促使临床医生重新评估处方模式和风险获益权衡。同时，旨在改善起效时间、持续时间和耐受性的製剂科学进展，正在影响产品在门诊和住院环境中的定位。

同时，支付方的严格审查和监管指导迫使製药公司透过真实世界数据和疗效比较研究来证明其差异化价值。数位疗法和远端患者监护正在重新定义辅助治疗模式，从而实现结合行为疗法和药物疗法的阶梯式治疗方案。此外，以病人为中心的包装和替代给药途径也日益受到重视，成为提高病人依从性的有效途径。总而言之，这些变化正在重塑竞争格局，刺激对标靶研发的投资，并支持策略合作，从而加速下一代失眠疗法的临床转化。

2025年关税调整和贸易趋势将如何推动失眠治疗价值链的供应链重组、购买多元化和韧性投资

包括2025年实施的关税调整在内的政策和贸易措施，为製药企业和经销商的全球供应链规划引入了新的变数。这些措施影响了部分进口原料药、辅料和成品药的成本基础，促使采购部门重新评估筹资策略和紧急库存。为此，许多企业正在加速供应商网路多元化，并更加重视近岸外包，以降低贸易波动带来的风险。

此外，不断变化的关税环境也促使各通路的服务交付成本受到更严格的审查。医院药局和大型零售连锁店正在审查采购合约和库存管理通讯协定，以缓解利润率下降的情况。同时，製造商正在重新评估生产基地选址和供应链韧性投资，优先考虑大量生产的灵活性和多基地认证。监管合规性和品质保证要求持续影响这些调整，企业越来越需要在关税驱动的成本压力与对可靠性和治疗完整性的承诺之间寻求平衡。

全面的細項分析揭示了治疗领域特征、剂型和给药途径的差异、分销动态和最终用户趋势等方面的见解，所有这些都可以用来製定目标策略。

细分市场分析揭示了不同治疗层级、製剂形式、给药途径、分销管道和终端用户环境对价值和需求的影响因素。药物类别包括抗组织胺、苯二氮平类、褪黑素受体促效剂、非苯二氮平类药物和Orexin受体拮抗剂。在非苯二氮平类药物中，一些具有重要临床意义的药物，例如依佐匹克隆、Zaleplon和Zolpidem，其起效时间和半衰期各不相同，这影响了它们的市场定位。同时，Orexin受体拮抗剂，例如达利多雷沙、伦博雷沙和苏沃雷沙，为处方医师的决策带来了新的疗效和耐受性的考量。这些差异导致了不同的临床评估和推广策略，有些药物更适合短期症状管理，而有些药物则更适合维持治疗。

从胶囊、注射到口服混悬液、舌下片和锭剂，多种剂型选择影响产品的差异化和患者偏好，而易用性和起效速度则赋予了产品竞争优势。给药途径——静脉注射、口服、舌下和经皮——进一步影响医院和门诊的用药情况，以及特定治疗方案在基层医疗和急诊环境中的可行性。分销通路细分突显了药局、医院药局、线上药局和零售药局在影响药物可近性和依从性方面所发挥的作用。在医院药局内部，公立和私立机构的采购行为有差异。线上药局分为一般B2C平台、厂商直销网站和远距药事照护服务，每种平台都有其独特的监管和商业特征。零售药局（连锁药局、独立药局和超级市场附属药局）的多样性影响着促销范围和销售点互动策略。将门诊中心、诊所、居家医疗和医院等终端使用者细分，可凸显不同的诊疗路径。医院本身又分为公立和私立两类，各自拥有不同的处方集流程和采购週期。整合这些细分观点，有助于相关人员更好地协调临床开发、行销和分销策略，从而满足目标处方医生和患者的细微需求。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和监管差异要求失眠药物的取得和分销策略具有适应性。

区域趋势持续影响产品策略、监管计划和分销网络设计。在美洲，临床实践模式以及公立和私立支付方之间的互动影响着药品目录的准入，而数位化医疗的普及和远距药事照护模式则扩大了门诊病人范围并提升了病人参与。美洲市场的准入考量通常着重于展示产品在实际应用中的功能性和安全性差异，以确保获得临床医生和支付方的青睐。

在欧洲、中东和非洲地区，不同的法规结构和采购环境要求制定适应性强的市场进入策略，以因应各国处方集、公立医院采购和私部门的差异。这些地区的临床医生在处方决策中优先考虑药物的长期耐受性和合併症情况，而公立和私立医疗系统的报销途径可能存在显着差异。在亚太地区，远端医疗的快速普及、多样化的报销机制以及不断发展的国内生产能力既带来了机会，也带来了挑战。相关人员正优先考虑在地化证据的产生、监管协调策略以及与区域经销商的合作，以应对采购惯例并加速在公立和私立医疗机构中的应用。在所有地区，供应链的韧性、与当地监管机构的合作以及符合当地文化的病患教育仍然是成功商业化的关键要素。

竞争和企业策略着重于差异化治疗方法、数位化协作、生命週期管理以及临床和商业性优势的证据产生。

主要企业之间的竞争特点在于，它们专注于有针对性的研发投资、建立合作伙伴关係以及生命週期管理，旨在维持产品的临床相关性。各公司正利用临床差异化优势，例如改善隔日认知功能和降低成瘾风险，以更好地向处方医生和支付方推广其后期研发和已上市产品。製药开发商与数位医疗供应商之间的策略联盟日益普遍，从而能够整合药物和行为解决方案，以解决药物依从性和长期治疗效果问题。

此外，一些製造商正在优化包装、患者援助计划和与专科药房的合作，以适应特定的分销管道和终端用户环境，从而推动商业化。併购和授权合约仍然是拓展产品组合和取得差异化作用战术性的有效策略。整体竞争格局日益着重于产生核准后证据，包括真实世界研究和註册研究，以支持产品价值主张并辅助健保报销谈判。在营运方面，各公司正在投资提升供应链灵活性和监管专业知识，以加快跨区域市场准入，同时保持高标准的品质和安全。

为产业领导者建立永续竞争优势提供实用策略指南：整合证据产生、数位整合、弹性供应链和个人化商业化

产业领导者应优先考虑整合临床差异化、切实可行的市场进入策略和稳健的供应链设计的方法。首先，他们应投资于有针对性的证据生成，以证明疗效比较、患者报告结局和真实世界安全性，从而支持药品目录的纳入和与支付方的对话。其次，他们应加强与数位医疗服务提供者的合作，创建整合式照护路径，以提高治疗依从性并扩大市场覆盖范围，尤其是在门诊和居家医疗领域。这种联合交付模式将增强对临床医生和支付方的价值提案。

同时，我们透过供应商多元化和筛选合格的替代製造地来优化生产和采购，从而降低贸易和关税相关中断的风险。我们利用客製化的价值提案材料和本地真实世界数据，加强与医院处方集委员会的合作，鼓励私营和公共部门儘早采用我们的产品。最后，我们客製化商业化策略，使製剂形式和给药途径与分销管道能力和终端用户需求相匹配，并确保通讯涵盖疗效和对日常生活的影响。这些倡议共同构成了一个协调一致的计划，兼顾了短期市场准入和长期品牌永续性。

为了确保解释的严谨性，我们采用了严谨的多方面调查方法，包括相关利益者访谈、监管审查、临床综合分析和供应链风险评估。

本研究采用多学科方法，结合定性和定量证据来源，旨在深入了解失眠治疗领域。主要研究包括对关键相关人员进行结构化访谈，这些利害关係人包括临床专家、处方集决策者、采购人员和分销合作伙伴，以收集有关推广驱动因素、安全顾虑和营运限制等方面的实地观点。次要研究则利用同行评审文献、监管指导文件、临床试验註册库和上市公司披露信息，对临床和监管趋势进行三角验证。

我们的分析方法包括临床对比分析、跨治疗领域、製剂形式、给药途径、分销管道和终端用户环境的细分市场分析，以及针对近期政策和关税变化的供应链风险检验。我们非常注重透过与多个独立资讯来源交叉核对和反覆的同侪审查来验证我们的研究结果。我们的调查方法强调资料来源的透明度和解读的严谨性，以确保我们的结论反映的是当前的实践模式和现行的监管环境，而非推测性的预测。

摘要重点阐述了以临床差异化、实证投资、灵活的供应策略和通路为核心的商业化策略，旨在推动持续影响。

总之，失眠治疗领域正受到机制特异性临床进展、安全性和日常功能预期变化以及分销和医疗服务模式变革的重塑。将产品开发与差异化临床特征相结合、投资于真实世界证据并采用灵活的生产和筹资策略的相关人员，将能够更有效地应对商业性和监管方面的复杂性。此外，整合数位健康模式并制定针对特定管道的商业化计划，对于扩大治疗覆盖范围和提高门诊及居家照护环境中的用药依从性至关重要。

展望未来，决策者应持续关注两方面：一方面是短期准入问题，例如药品目录定位和供应链韧性；另一方面是长期投资于支持差异化价值的实证医学证据。这将使各机构能够在负责任地满足支付方和临床医生需求的同时，建立可持续的竞争优势。后续可执行的建议以及与商业和咨询资源的客製化合作，将有助于将这些策略方向转化为能够带来可衡量成果的营运计画。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• Orexin受体拮抗剂的快速成长，得益于真实世界中安全性和有效性证据的持续累积。
• 将数位疗法和认知行为疗法模组与失眠药物结合，以创建个人化治疗方案
• 新冠肺炎相关睡眠感染疾病对处方模式和失眠药物长期需求的影响
• 由于担心成瘾性和认知风险，Z类药物将受到更严格的监管审查和上市后监测。
• 人们对褪黑激素促效剂在儿童和老年人失眠治疗策略中的应用越来越感兴趣，希望扩大仿单标示外。
• 非镇静性抗焦虑药物的研发及临床试验进展（针对伴随忧郁症的失眠）
• 穿戴式睡眠监测设备和人工智慧驱动的分析技术的出现，将使失眠药物的剂量能够即时调整。
• 新型双重Orexin受体拮抗剂上市，带来激烈的药品目录竞争与价格压力。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的失眠治疗市场

• 抗组织胺药
• 苯二氮平类药物
• 褪黑素受体促效剂
• 非苯二氮平类药物
  • 依佐匹克隆
  • Zaleplon
  • Zolpidem
• Orexin受体拮抗剂
  • 达里德雷桑特
  • 伦博雷桑
  • 苏沃雷桑

9. 依配方分類的失眠治疗市场

• 胶囊
• 注射
• 口服悬浮液
• 舌下片
• 药片

第十章 依给药途径分類的失眠治疗市场

• 静脉注射
• 口服
• 舌下给药
• 经皮

第十一章 按分销管道分類的失眠治疗市场

• 药局
• 医院药房
  • 私立医院
  • 公立医院
• 网路药房
  • 通用B2C平台
  • 厂商直销网站
  • 远距药事照护服务
• 零售药房
  • 连锁药局
  • 独立药房
  • 超级市场药房

第十二章：失眠治疗市场（依最终用户划分）

• 门诊治疗中心
• 诊所
• 居家医疗
• 医院
  • 私立医院
  • 公立医院

第十三章：各地区的失眠治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 失眠治疗市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国失眠治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Avadel Pharmaceuticals plc
  • Idorsia Ltd.
  • Viatris Inc.

The Insomnia Drugs Market is projected to grow by USD 4.87 billion at a CAGR of 5.91% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.07 billion
Estimated Year [2025]	USD 3.25 billion
Forecast Year [2032]	USD 4.87 billion
CAGR (%)	5.91%

A concise contextual introduction framing therapeutic innovation, clinical pressures, and commercial drivers that shape the modern insomnia treatment landscape

The insomnia drugs landscape is undergoing rapid evolution driven by scientific advances, shifting patient expectations, and intensifying regulatory attention. This executive summary introduces the critical themes that shape current and near-term decision-making for stakeholders across pharmaceutical development, clinical practice, distribution, and payer engagement. The overview synthesizes therapeutic innovations, changing consumption patterns, and the infrastructure supporting treatment delivery, offering a clear entry point for leaders seeking to align investments with emerging opportunities.

Importantly, this introduction situates insomnia within a broader healthcare context where comorbid psychiatric and cardiometabolic conditions influence both therapeutic choices and adherence. It highlights how pharmacological differentiation, safety profiles, and convenience of administration increasingly determine clinician preference and patient uptake. The section sets expectations for the subsequent analysis by outlining methodological rigor and the multi-dimensional lens-clinical, regulatory, commercial-used to interpret trends. Readers are invited to proceed with a focus on strategic implications rather than historical volume metrics, as the subsequent sections prioritize actionable insights that support portfolio and market-access decisions.

An analysis of paradigm-shifting clinical advances, payer expectations, and care-delivery innovations that are reshaping insomnia drug development and adoption

The insomnia therapeutics environment is experiencing transformative shifts shaped by innovation in mechanism of action, heightened safety expectations, and digital-enabled care pathways. Novel compounds targeting orexin receptors have recalibrated clinical conversations about efficacy and next-day functioning, prompting clinicians to reassess prescribing patterns and risk-benefit trade-offs. Concurrently, advances in formulation science-aimed at improving onset, duration, and tolerability-are influencing how products are positioned across ambulatory and institutional settings.

Meanwhile, payer scrutiny and regulatory guidance are prompting manufacturers to demonstrate differentiated value through real-world evidence and comparative-effectiveness studies. Digital therapeutics and remote patient monitoring are redefining adjunctive treatment models, enabling stepped-care approaches that combine behavioral and pharmacologic interventions. Additionally, patient-centric packaging and alternative routes of administration are gaining attention as adherence drivers. Collectively, these shifts are altering competitive dynamics, funneling investment into targeted R&D, and encouraging strategic partnerships that accelerate time-to-clinic for next-generation insomnia solutions.

How 2025 tariff adjustments and trade dynamics are prompting supply chain redesigns, procurement diversification, and resilience investments across the insomnia drug value chain

Policy and trade actions, including tariff adjustments implemented in 2025, have introduced new variables into global supply chain planning for pharmaceutical manufacturers and distributors. These measures have affected the cost base for certain imported active pharmaceutical ingredients, excipients, and finished formulations, prompting procurement teams to reassess sourcing strategies and contingency inventories. In response, many organizations have accelerated diversification of supplier networks and increased emphasis on nearshoring to reduce exposure to trade-related volatility.

In addition, the tariff landscape has intensified scrutiny of cost-to-serve calculations across distribution channels. Hospital pharmacies and large retail chains have re-evaluated procurement agreements and inventory management protocols to mitigate margin compression. Meanwhile, manufacturers have revisited manufacturing footprints and supply chain resilience investments, prioritizing flexibility in batch sizes and multi-site qualification. Regulatory compliance considerations and quality assurance requirements continue to shape these adjustments, and companies are increasingly balancing tariff-driven cost pressures with commitments to reliability and therapeutic integrity.

Comprehensive segmentation intelligence revealing therapeutic class nuances, formulation and administration distinctions, distribution dynamics, and end-user patterns that inform targeted strategies

Segmentation analysis reveals differentiated drivers of value and demand across therapeutic class, formulation, route of administration, distribution channel, and end-user settings. The drug class dimension encompasses antihistamines, benzodiazepines, melatonin receptor agonists, non-benzodiazepines, and orexin receptor antagonists; within the non-benzodiazepine category, clinically relevant agents such as eszopiclone, zaleplon, and zolpidem demonstrate varying profiles of onset and half-life that influence positioning, while orexin receptor antagonists including daridorexant, lemborexant, and suvorexant have introduced a distinct efficacy and tolerability conversation into prescriber decision-making. These differences drive divergent clinical narratives and promotional strategies, with some classes remaining more attractive for short-term symptom control and others suited for maintenance therapy considerations.

Formulation choices-ranging from capsules, injectables, oral suspensions, sublingual tablets, to tablets-are shaping product differentiation and patient preference, as ease of use and onset characteristics become competitive levers. Route-of-administration distinctions, including intravenous, oral, sublingual, and transdermal options, further influence hospital versus outpatient utilization and the feasibility of certain therapeutic approaches in primary care or acute settings. Distribution channel segmentation highlights the role of drug stores, hospital pharmacies, online pharmacies, and retail pharmacies in shaping access and adherence; within hospital pharmacies, private and public institutions exhibit differing procurement behaviors, while online pharmacies segment into general B2C platforms, manufacturer direct sites, and telepharmacy services, each presenting unique regulatory and commercial dynamics. Retail pharmacy variations-chain, independent, and supermarket pharmacies-affect promotional reach and point-of-sale engagement strategies. End-user segmentation across ambulatory care centers, clinics, home care, and hospitals underscores divergent care pathways; hospitals themselves differentiate into private and public entities with distinct formulary processes and procurement cycles. By integrating these segmentation lenses, stakeholders can better tailor clinical development, marketing, and distribution tactics to match the nuanced needs of targeted prescribers and patients.

Regional dynamics and regulatory diversity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that require adaptive access and distribution strategies for insomnia therapies

Regional dynamics continue to shape product strategy, regulatory planning, and distribution network design. In the Americas, clinical practice patterns and the interplay between private and public payers influence formulary access, while digital health adoption and telepharmacy models are expanding outpatient reach and patient engagement. Market entry considerations in the Americas often revolve around demonstrating differentiation in real-world functioning and safety to secure favorable positioning with both clinicians and payers.

Within Europe, Middle East & Africa, heterogeneous regulatory frameworks and procurement environments demand adaptive market-access strategies that account for national formularies, public hospital procurement, and private-sector variability. Clinicians across these geographies weigh long-term tolerability and comorbidity profiles heavily in prescribing decisions, and reimbursement pathways can vary significantly between public and private systems. In the Asia-Pacific region, rapid uptake of telemedicine, diverse reimbursement mechanisms, and evolving domestic manufacturing capabilities present both opportunities and complexity. Stakeholders are prioritizing localized evidence generation, regulatory alignment strategies, and partnerships with regional distributors to navigate procurement practices and expedite adoption across public and private healthcare settings. Across all regions, supply chain resilience, local regulatory engagement, and culturally informed patient education remain essential components of successful commercialization.

Competitive and corporate maneuvers emphasizing therapeutic differentiation, digital collaborations, lifecycle management, and evidence generation to secure clinical and commercial advantage

Competitive behavior among leading organizations is characterized by targeted R&D investment, alliance formation, and a focus on lifecycle management aimed at sustaining clinical relevance. Companies are leveraging clinical differentiation, such as improved next-day cognitive profiles and minimized dependency risks, to position late-stage and marketed products more favorably with prescribers and payers. Strategic collaborations between pharmaceutical developers and digital health vendors are becoming more commonplace, enabling combined pharmacologic and behavioral offerings that address adherence and long-term outcomes.

Additionally, some manufacturers are optimizing commercialization by tailoring packaging, patient-support programs, and specialty pharmacy partnerships to specific distribution channels and end-user settings. Mergers, acquisitions, and licensing agreements remain tactical options for expanding portfolios or acquiring differentiated mechanisms of action. Across the competitive landscape, there is increasing emphasis on generating post-approval evidence, including real-world studies and registries, to substantiate value claims and support reimbursement negotiations. Operationally, firms are investing in supply chain flexibility and regulatory expertise to accelerate market entry across multiple geographies while maintaining high standards of quality and safety.

Actionable strategic directives for industry leaders to align evidence generation, digital integration, resilient supply chains, and tailored commercialization for sustainable advantage

Industry leaders should prioritize an integrated approach that aligns clinical differentiation with pragmatic market-access strategies and resilient supply chain design. First, invest in targeted evidence generation that demonstrates comparative effectiveness, patient-reported outcomes, and real-world safety to support formulary inclusion and payer dialogues. Secondly, pursue partnerships with digital health providers to create bundled care pathways that improve adherence and extend market reach, particularly in outpatient and home-care settings. Such combined offerings will enhance value propositions to both clinicians and payers.

Concurrently, optimize manufacturing and procurement by diversifying suppliers and qualifying alternate sites to mitigate exposure to trade and tariff-related disruption. Strengthen engagement with hospital formulary committees through tailored value dossiers and locally relevant real-world data to expedite acceptance in both private and public institutions. Finally, tailor commercialization strategies by aligning formulation and route preferences with distribution channel capabilities and end-user needs, ensuring that messaging addresses both efficacy and daily-life impact. Together, these actions create a coherent plan that balances short-term access priorities with long-term brand sustainability.

A rigorous multi-source research methodology integrating stakeholder interviews, regulatory review, clinical synthesis, and supply chain risk assessment to ensure interpretive rigor

This research employed a multi-disciplinary methodology combining qualitative and quantitative evidence sources to build a robust understanding of the insomnia therapeutic landscape. Primary research involved structured interviews with key stakeholders, including clinical experts, formulary decision-makers, procurement leads, and distribution partners, to capture frontline perspectives on adoption drivers, safety concerns, and operational constraints. Secondary research utilized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate clinical and regulatory trends.

Analytical techniques included comparative clinical profiling, segmentation mapping across therapeutic class, formulation, route of administration, distribution channel, and end-user settings, and supply chain risk assessment focused on recent policy and tariff developments. Care was taken to validate insights through cross-referencing multiple independent sources and through iterative expert review. The methodology emphasizes transparency in data sourcing and interpretive rigor, ensuring that conclusions reflect current practice patterns and the prevailing regulatory landscape rather than speculative projections.

A concluding synthesis emphasizing clinical differentiation, evidence investment, flexible supply strategies, and channel-focused commercialization to drive sustainable impact

In conclusion, the insomnia drugs domain is being reshaped by mechanism-specific clinical advances, evolving expectations for safety and daily functioning, and shifts in distribution and care-delivery models. Stakeholders who align product development with differentiated clinical profiles, invest in real-world evidence, and adopt flexible manufacturing and procurement strategies will be better positioned to navigate commercial and regulatory complexity. Additionally, integrating digital health modalities and designing channel-specific commercialization plans will be critical to expanding reach and improving adherence in outpatient and home-care settings.

Moving forward, decision-makers should maintain a dual focus on near-term access imperatives-such as formulary positioning and supply chain resilience-and longer-term investments in evidence that supports differentiated value. By doing so, organizations can create durable competitive advantage while responding responsibly to payer and clinician priorities. The subsequent actionable recommendations and tailored engagement with sales and advisory resources can help translate these strategic directions into operational plans that deliver measurable outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid growth of orexin receptor antagonists supported by emerging real-world safety and efficacy evidence
• 5.2. Integration of digital therapeutics and cognitive behavioral therapy modules with insomnia drugs for personalized treatment pathways
• 5.3. Impact of COVID-19-induced sleep disturbances on prescription patterns and long-term demand for insomnia medications
• 5.4. Regulatory scrutiny and post-marketing surveillance intensification for Z-drugs amid dependency and cognitive risk concerns
• 5.5. Surging interest in melatonin receptor agonists for expanding off-label use in pediatric and geriatric insomnia management strategies
• 5.6. Development and clinical trial advancements of non-sedative anxiolytic compounds targeting insomnia with comorbid depression
• 5.7. Emergence of wearable sleep monitoring devices and AI-driven analytics guiding real-time dose adjustment of insomnia drugs
• 5.8. Market entry of novel dual orexin receptor antagonists driving competitive formulary placement and pricing pressures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Drugs Market, by Drug Class

• 8.1. Antihistamines
• 8.2. Benzodiazepines
• 8.3. Melatonin Receptor Agonists
• 8.4. Non-Benzodiazepines
  • 8.4.1. Eszopiclone
  • 8.4.2. Zaleplon
  • 8.4.3. Zolpidem
• 8.5. Orexin Receptor Antagonists
  • 8.5.1. Daridorexant
  • 8.5.2. Lemborexant
  • 8.5.3. Suvorexant

9. Insomnia Drugs Market, by Formulation

• 9.1. Capsules
• 9.2. Injectables
• 9.3. Oral Suspensions
• 9.4. Sublingual Tablets
• 9.5. Tablets

10. Insomnia Drugs Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Sublingual
• 10.4. Transdermal

11. Insomnia Drugs Market, by Distribution Channel

• 11.1. Drug Stores
• 11.2. Hospital Pharmacies
  • 11.2.1. Private Hospitals
  • 11.2.2. Public Hospitals
• 11.3. Online Pharmacies
  • 11.3.1. General B2C Platforms
  • 11.3.2. Manufacturer Direct Sites
  • 11.3.3. Telepharmacy Services
• 11.4. Retail Pharmacies
  • 11.4.1. Chain Pharmacies
  • 11.4.2. Independent Pharmacies
  • 11.4.3. Supermarket Pharmacies

12. Insomnia Drugs Market, by End User

• 12.1. Ambulatory Care Centers
• 12.2. Clinics
• 12.3. Home Care
• 12.4. Hospitals
  • 12.4.1. Private Hospitals
  • 12.4.2. Public Hospitals

13. Insomnia Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Insomnia Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Insomnia Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Sanofi S.A.
  • 16.3.2. Sunovion Pharmaceuticals Inc.
  • 16.3.3. Merck & Co., Inc.
  • 16.3.4. Eisai Co., Ltd.
  • 16.3.5. Takeda Pharmaceutical Company Limited
  • 16.3.6. Johnson & Johnson
  • 16.3.7. Teva Pharmaceutical Industries Ltd.
  • 16.3.8. Avadel Pharmaceuticals plc
  • 16.3.9. Idorsia Ltd.
  • 16.3.10. Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. INSOMNIA DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 257. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 258. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 270. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 271. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 272. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 273. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 274. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 275. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 276. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 277. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 280. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 281. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 284. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 285. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
• TABLE 286. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
• TABLE 287. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 288. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 289. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 290. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 291. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 292. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 293. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 294. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 295. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 296. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 297. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 298. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 299. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 300. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 301. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 302. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 303. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 304. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 305. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 308. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 309. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)
• TABLE 310. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2025-2032 (USD MILLION)
• TABLE 311. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 312. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 313. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 314. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 315. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 316. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 317. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 318. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 319. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 320. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 321. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 322. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 323. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
• TABLE 324. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
• TABLE 325. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 327. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 328. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 329. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 330. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 331. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 332. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 333. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2024 (USD MILLION)

TABLE 334